Exbivirumab

Exbivirumab is a human monoclonal antibody^[1] developed for the treatment of hepatitis B infections.^[2]

References

↑ WHO Drug Information
↑ Shouval, D et al. (2006). "Anti-Viral Effects, Pharmacokinetics and Safety of Two Human Monoclonal Anti-Hbs (Libivirumab/Exbivirumab) Versus Hepatitis B Immune Globulin (Hbig) in Hepatits B Virus (Hbv) in Liver Transplant (Lt) Recipients". Hepatology 44 (4): 188A–700A [196A]. doi:10.1002/hep.21395. PMID 17001593.

Monoclonal antibodies for infectious disease and toxins

Fungal ("-fung-")

Human ("-fungu-")	Efungumab

Viral ("-vi(r)-")

Human ("-viru-")	Exbivirumab Foravirumab Libivirumab Rafivirumab Regavirumab Sevirumab Tuvirumab

Humanized ("-vizu-")	Felvizumab Motavizumab Palivizumab Suvizumab

Bacterial ("-ba(c)-")

Human ("-bacu-")	Nebacumab Panobacumab Raxibacumab

Mouse ("-baco-")	Edobacomab

Chimeric ("-baxi-")	Pagibaximab

Humanized ("-bazu-")	Tefibazumab^†

Toxin ("-tox(a)-")